Petros Pharmaceuticals Inc. (PTPI): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTPI Stock Price Chart Interactive Chart >
PTPI Price/Volume Stats
| Current price | $0.83 | 52-week high | $5.20 |
| Prev. close | $0.90 | 52-week low | $0.65 |
| Day low | $0.82 | Volume | 227,569 |
| Day high | $0.90 | Avg. volume | 1,299,449 |
| 50-day MA | $0.95 | Dividend yield | N/A |
| 200-day MA | $1.71 | Market Cap | 17.17M |
Petros Pharmaceuticals Inc. (PTPI) Company Bio
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
Latest PTPI News From Around the Web
Below are the latest news stories about Petros Pharmaceuticals Inc that investors may wish to consider to help them evaluate PTPI as an investment opportunity.
Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's HealthPetros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a collaboration agreement with celebrity physician Dr. Drew Pinsky ("Dr. Drew") to raise awareness, foster dialogue, educate, and alleviate the stigma of erectile dysfunction (ED) and sexual dysfunction within the men's health and wellness landscape. Through this collaboration, Dr. Drew is expected to utilize his medical expertise and social media channels on behal |
Petros Pharma forms partnership for U.S. production of erectile dysfunction drug StendraPetros Pharmaceuticals (PTPI -6.0%) has partnered with a Contract Development and Manufacturing Organization (CDMO), for commercial production of STENDRA (avanafil) tablets. The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the product to the U.S., and is expected to provide both cost savings and increase... |
Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ (avanafil) to the United StatesPetros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces it has partnered with a leading Contract Development and Manufacturing Organization (CDMO), for commercial production of STENDRA (avanafil) tablets. The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the product to the United States, and is expected to provide both cost savings and increase in gross margin. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investor! |
Petros Pharmaceuticals initiates 2 self-selection studies for erectile dysfunction drugPetros Pharmaceuticals (PTPI) initiated two self-selection studies for its erectile dysfunction ((ED)) drug STENDRA (avanafil).The company said the results of these studies will be part |
PTPI Price Returns
| 1-mo | N/A |
| 3-mo | -46.79% |
| 6-mo | -75.08% |
| 1-year | -73.57% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -75.08% |
| 2021 | -24.32% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...